• Go to navigation
  • Go to content
Faslodex fulvestrant

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca

Main navigation

  • Home
  • FASLODEX
    • Efficacy
    • Safety and Tolerability
    • Mechanism of Action
  • Prescribing Information
    • Dosage and Administration
  • Indication
    • Breast cancer
  • Key Studies
    • CONFIRM Trial
    • 0020/0021 Trials
  • Glossary

You are here

  • Home

  • FASLODEX clinical trials

Clinical trials have confirmed the efficacy and safety profile of FASLODEX 500 mg and 250 mg.1-3 These FASLODEX clinical trials contributed to, and support, the current indication:

The CONFIRM trial
Studies 0020 and 0021

Header functions

    • AstraZeneca websites
    • Contact Us
    • Glossary

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2012

  • Last updated: 30/09/2011

    • Terms of use
    • Privacy policy
    • Compliance information
    • ©2012 AstraZeneca LP. All rights reserved. 283 189 7/09